Stereotaxis Announces Convertible Note Financing of Up To $24 Million

The notes add interest obligations and potential share dilution, while the optional second draw depends on regulatory milestones.

Rhea-AI Summary

Stereotaxis (NYSE: STXS) has signed definitive agreements with investors for convertible note financing of up to $24 million. The financing includes an initial upfront closing of $12 million and an additional $12 million available at the company's option following certain regulatory milestones.

The notes carry 10% annual interest, accrued and due at maturity in three years. They may convert into common stock at $1.21 per share, a 30% premium to the 10-day volume-weighted average share price before closing. Pro forma cash and cash equivalents are $16 million, with access to an additional $12 million bringing total availability to $28 million. Stereotaxis believes the financing bridges it to profitability. Net proceeds will support working capital, product commercialization, research and development, and other general corporate purposes.

4 points · 0 major

MixediHow this balance works

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

How the balance worksHow Sentiment works

0 major · 3 points

Hollow bars mark forward-looking points. How the balance works

Positive

• Moderate point. Forward-looking: it has not happened yet and may not happen.Definitive financing agreements include an initial $12 million upfront closing. 11% of market cap
• Minor point. Forward-looking: it has not happened yet and may not happen.Pro forma cash and cash equivalents total $16 million with the financing.
• Minor pointThe $1.21 conversion price represents a 30% premium to the 10-day volume-weighted average price before closing.
• Minor point. Forward-looking: it has not happened yet and may not happen.Stereotaxis believes the financing bridges the company to profitability.

Negative

• Moderate point. Forward-looking: it has not happened yet and may not happen.Conversion into common stock at $1.21 per share would dilute existing shareholders.
• Minor pointConvertible notes carry 10% annual interest, accrued and due at maturity in three years.
• Minor point. Forward-looking: it has not happened yet and may not happen.The optional additional $12 million draw depends on certain regulatory milestones.

Argus 15 min delay 13 alerts

-13.71% vs previous close $0.8888 last price 1.2x rel. volume Open Argus

Details

Market move: STXS -13.71% vs previous close. convertible note financing

$0.87 – $1.24 Day Range

$89.06M Mkt Cap at Last Price

On Nov 10, the day this news came out, the latest delayed price for STXS is 13.71% below the previous close. Our momentum scanner has recorded 13 alerts for this stock so far that day. The latest delayed price is $0.89.

Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.

Key Figures

Maximum financing: Up to $24 million Initial closing: $12 million Additional draw: $12 million +5 more

Maximum financing

Up to $24 million

Convertible note financing

Initial closing

$12 million

Upfront closing

Additional draw

$12 million

Available at the company's option following certain regulatory milestones

Annual interest rate

10%

Interest accrues and is due at maturity

Maturity

Three years

Interest due at maturity

Conversion price

$1.21 per share

Convertible notes may convert into common stock

Conversion-price premium

30%

Premium to the 10-day volume weighted average price before closing

Cash and total availability

$16 million pro forma cash and cash equivalents; $28 million total availability

Includes access to an additional $12 million

Key Terms

convertible note, volume weighted average price, form 8-k

3 terms

convertible note financial

"definitive agreements with investors for a convertible note financing"

A convertible note is a type of loan that a company gets from investors, which can later be turned into company shares instead of being paid back in cash. It matters because it helps startups raise money quickly without setting a fixed value for the company right away, making it easier to grow and attract investors.

volume weighted average price financial

"30% premium to the 10-day volume weighted average price"

The volume weighted average price (VWAP) is a way to measure the average price of a security, such as a stock, over a specific period, taking into account how many units were traded at each price. It’s similar to calculating the average cost of items bought when some are more frequently purchased than others. Investors use VWAP to assess whether a security is being bought or sold at a fair price during trading.

form 8-k regulatory

"included in the Form 8-K to be filed by Stereotaxis"

A Form 8-K is a report that companies file with the government to share important news quickly, such as changes in leadership, major business deals, or financial updates. It matters because it helps investors stay informed about significant events that could affect the company's value or stock price.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

ST. LOUIS, Nov. 10, 2026 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced it has entered into definitive agreements with investors for a convertible note financing of up to $24 million.

“We appreciate the confidence and support from several of our long-term shareholders in this oversubscribed financing,” said David Fischel, Chairman and CEO. “Our strengthened balance sheet positions us to execute our strategy and accelerate adoption of our comprehensive portfolio of innovations.”

The financing includes an initial upfront closing of $12 million, and an additional $12 million draw available at Stereotaxis’ option following certain regulatory milestones. The notes carry a 10% annual interest rate, with interest accrued and due at maturity in three years. The notes may be converted into common stock at a conversion price of $1.21 per share, a 30% premium to the 10-day volume weighted average price of Stereotaxis’ common stock prior to closing of the financing.

With this financing, Stereotaxis has $16 million in proforma cash and cash equivalents, with access to an additional $12 million, for total availability of $28 million. The structure of the financing reflects Stereotaxis’ belief that this financing bridges the Company to profitability.

Net proceeds from the financing will be used for working capital, to accelerate product commercialization, research and development, and other general corporate purposes. Additional details on the financing and convertible note securities will be included in the Form 8-K to be filed by Stereotaxis with the Securities and Exchange Commission. This press release does not constitute an offer to sell or the solicitation of an offer to buy, nor shall it constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale is unlawful.

About Stereotaxis
Stereotaxis (NYSE: STXS) is a pioneer and global leader in innovative surgical robotics for minimally invasive endovascular intervention. Its mission is the discovery, development and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide unsurpassed patient care with robotic precision and safety, expand access to minimally invasive therapy, and enhance the productivity, connectivity, and intelligence in the operating room. Stereotaxis technology has been used to treat over 150,000 patients across the United States, Europe, Asia, and elsewhere. For more information, please visit www.stereotaxis.com.

This press release includes statements that may constitute "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934, including statements regarding the completion of the Company’s convertible note financing, the ability to draw additional funds under the convertible note financing following receipt of required regulatory approvals and the anticipated use of proceeds therefrom, usually containing the words "believe”, "estimate”, "project”, "expect" or similar expressions. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially. Factors that would cause or contribute to such differences include, but are not limited to, uncertainties involving the following: the Company's ability to manage expenses at sustainable levels; acceptance of the Company's products in the marketplace, the effect of global economic conditions on the ability and willingness of customers to purchase its technology; competitive factors; changes resulting from healthcare policy, dependence upon third-party vendors; timing of regulatory approvals including as it relates to both the products of our recently acquired subsidiary, Robocath, and our ability to make further draws on the convertible note financing, the impact of pandemics or other disasters, statements generally relating to our recent acquisition of Robocath or our recently announced convertible note financing, including any benefits expected from either of those transactions, as well as any plans, forecasts and other expectations with respect to Robocath’s business following the completion of the transaction; and other risks discussed in the Company's periodic and other filings with the SEC. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this press release. There can be no assurance that the Company will recognize revenue related to customer purchase orders and other commitments because some of these purchase orders and other commitments are subject to contingencies that are outside of the Company's control and may be revised, modified, delayed, or canceled.

Stereotaxis Contacts:
David L. Fischel
Chairman and Chief Executive Officer

Kimberly Peery
Chief Financial Officer

314-678-6100
Investors@Stereotaxis.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How much financing has Stereotaxis arranged?

Stereotaxis has signed definitive agreements for up to $24 million in convertible note financing. The structure includes an initial upfront closing of $12 million and an additional $12 million draw available at the company's option following certain regulatory milestones.

What are the interest and conversion terms of Stereotaxis' convertible notes?

The notes carry 10% annual interest, accrued and due at maturity in three years, and may convert into common stock at $1.21 per share. That conversion price represents a 30% premium to the 10-day volume-weighted average share price before closing.